Navigation Links
Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
Date:12/9/2008

Data Support Case for DNA-Guided Medicine in Psychiatry

HARTFORD, Conn., Dec. 9 /PRNewswire/ -- Results from a clinical study published in the current issue of the Future Medicine Group (London) journal Personalized Medicine (Vol. 5, No. 6, pp. 579-587, 2008) are helping to point the way toward the application of DNA-guided medicine to predict psychotropic side effects. The study was conducted at The Institute of Living of Hartford Hospital in collaboration with Genomas.

The CYP2C9, CYP2C19 and CYP2D6 genes from the cytochrome P450 family were chosen for DNA typing because their common variants result in deficient metabolic capacity for many psychotropic drugs. Combinatorial gene analysis revealed that 57 percent of individuals in the psychiatric population were carriers of multiple gene variations associated with no or poor drug metabolism capacity on 2 or 3 genes compared to 36 percent of individuals in the control population. Individuals that are multiply deficient in CYP450 metabolic routes are at risk for developing serious side effects to a variety of psychotropic medications.

"We found clear evidence that there were significantly more innate drug metabolism deficiencies based on the gene variants predominantly observed in the population experiencing side effects," said Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, and Director of Genetics Research, Hartford Hospital. "Our goal is to enhance patient safety by preventing predictable side effects and at the same time build the case for DNA typing in the optimized utilization of health care resources. We are integrating this clinical experience with development of our PhyzioType Systems for DNA-Guided Medicine."

ABOUT GENOMAS

Genomas(R) Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. www.genomas.net


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2019)... ... February 13, 2019 , ... ... population health reporting solutions, is launching IMAT 8.0, its latest health data platform, ... a more streamlined user interface and dynamic single-query builder, IMAT 8.0 allows HIEs, ...
(Date:2/13/2019)... ... February 13, 2019 , ... Abu ... Public Private Partnership (PPP) between the Department of Health-Abu Dhabi (DoH) and Injazat ... Health Information Exchange system (HIE), a centralized platform to streamline healthcare connectivity for ...
(Date:2/13/2019)... ... February 13, 2019 , ... Co-founded in a parking lot by ... women an empowering place to not only exercise, but to nurture their mental and ... a former professional baseball player with the San Francisco Giants and COO Morgan brings ...
Breaking Medicine Technology:
(Date:2/13/2019)... ... , ... Infertility is an issue for 1 in 6 couples; in about 50% of these ... sharp decline in male sperm count over the last 40 years was featured in articles ... panic that we are in the midst of a severe, perhaps irreversible, male infertility crisis. ...
(Date:2/13/2019)... ... February 13, 2019 , ... A Place at Home has received ... Pulse. The Employer of Choice Award is granted only to the top-ranking home care ... research firm for home care. A Place at Home is ranked among the best ...
(Date:2/13/2019)... Calif. (PRWEB) , ... February 13, 2019 , ... Asana ... scholarship. Open to students who choose to pursue a medical-related course of study in ... their passion for substance abuse disorder and mental health treatment, and how it has ...
(Date:2/13/2019)... SANTA MONICA, Calif. (PRWEB) , ... February 13, ... ... Surgeon of Southern California has joined the esteemed Haute Beauty network. , ... is privileged to present Dr. Christie as a leading Aesthetic surgeon and our ...
(Date:2/12/2019)... ... February 12, 2019 , ... A technology company that aims ... visit, won the top award at the 9th annual SPIE Startup Challenge at ... winning pitch, nabbing a combined first prize of $15,000. Radiance 4D’s revolutionary 3D ...
Breaking Medicine News(10 mins):